500,000 More Mpox Vaccines Heading to Africa

Bavarian Nordic A/S and Gavi today announced an advance purchase agreement (APA) to secure 500,000 doses of the MVA-BN® mpox vaccine (JYNNEOS® or IMVANEX®).

These vaccines are being supplied to African countries impacted by the current mpox clade 1 outbreak.

Bavarian Nordic is ready to supply the mpox/smallpox vaccines pending signing a supply agreement with UNICEF, Gavi’s alliance partner, which will deliver these doses in 2024.

Paul Chaplin, President & CEO of Bavarian Nordic, commented in a press release on September 18, 2024, “The doses secured through this APA will significantly increase the availability of mpox vaccines for African countries, and we are pleased that Gavi has selected our MVA-BN vaccine, which has proven highly effective during the global mpox (clade 2) outbreak in 2022.”

The vaccines will be funded by Gavi, the Vaccine Alliance's First Response Fund, a new financial mechanism created in June 2024 to make cash available to purchase vaccines in health emergencies rapidly.

As of September 2024, there are four mpox vaccines available globally.